Dry powder drug delivery formulations, methods of use, and devices therefore
First Claim
1. A single unit dosage form for pulmonary delivery of an adrenergic agonist, comprising a single unit dosage receptacle containing a single delivery dosage amount of at least 20 mg of the adrenergic agonist as an essentially solvent free powder milled to an average particle size of less than about 10 μ
- m, and a pharmaceutically acceptable single dose quantity of a non-CFC haloalkane propellant.
2 Assignments
0 Petitions
Accused Products
Abstract
The present disclosure relates to systems, methods, and formulations for the pulmonary administration of one or more therapeutic agents, in dry powder form, in a single, large dose quantity. These formulations, methods, and systems are useful in the treatment of patients suffering from toxic or harmful gas exposure, such as nerve gas exposure, as well as in the treatment of patients suffering from diseases of the pulmonary system, including tuberculosis, cystic fibrosis, and chronic obstructive pulmonary disease (COPD).
34 Citations
10 Claims
-
1. A single unit dosage form for pulmonary delivery of an adrenergic agonist, comprising a single unit dosage receptacle containing a single delivery dosage amount of at least 20 mg of the adrenergic agonist as an essentially solvent free powder milled to an average particle size of less than about 10 μ
- m, and a pharmaceutically acceptable single dose quantity of a non-CFC haloalkane propellant.
- View Dependent Claims (2, 3, 4, 5, 6)
-
7. A method for aerosolizing a bioactive adrenergic agonist composition, the method comprising:
providing an aerosol delivery system that comprises at least two separate chambers separated by a valve, one propellant chamber comprising a pharmaceutically acceptable single dose quantity of propellant and a second active agent chamber comprising an essentially solvent free dry powder drug composition that includes an adrenergic agonist, wherein the system is adapted and dimensioned to admix and deliver at least 20 mg of the adrenergic agonist in one emergency treatment when the valve separating the chambers is opened and the propellant mixes with the drug composition and forms an aerosol for inhalation by a patient upon release from the system. - View Dependent Claims (8, 9, 10)
Specification